

ORIGINAL ARTICLE

Respiratory health and disease in a UK population-based cohort of 85 year olds: The Newcastle 85+ Study

Andrew J Fisher,^{1,2} Mohammad E Yadegarfar,^{2,3} Joanna Collerton,^{2,3} Therese Small,¹ Thomas B L Kirkwood,² Karen Davies,² Carol Jagger,^{2,3} Paul A Corris^{1,2}

ABSTRACT

► Additional material is published online only. To view this file please visit the journal online (http://dx.doi.org/10. 1136/thoraxjnl-2015-207249)

¹Department of Respiratory Medicine, Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle Upon Tyne, UK ²Institute for Ageing, Newcastle University

Newcastle University, Newcastle Upon Tyne, UK ³Faculty of Medical Sciences, Institute of Health and Society, Newcastle Upon Tyne, UK

Correspondence to


Professor Andrew J Fisher, Faculty of Medical Sciences, Institute for Ageing, Newcastle University, Framlington Place, Newcastle Upon Tyne NE2 4HH, UK; a.j.fisher@ncl.ac.uk

AJF and MEY contributed equally.

Received 30 April 2015 Revised 11 November 2015 Accepted 18 November 2015 Published Online First 5 January 2016







Background People aged 85 years and older are the fastest growing age group worldwide. This study assessed respiratory health, prevalence of respiratory disease and use of spirometry in respiratory diagnosis in a population-based cohort of 85 year olds to better understand respiratory health and disease in this sector of society.

Methods A single year birth-cohort of 85 year olds participated in a respiratory assessment at their home or residential institution including self-reporting of symptoms and measurement of spirometry. General practice medical records were reviewed for respiratory diagnoses and treatments.

Findings In the 845 participants, a substantial burden of respiratory disease was seen with a prevalence of COPD in medical records of 16.6% (n=140). A large proportion of the cohort had environmental exposures through past or current smoking (64.2%, n=539) and occupational risk factors (33.6%, n=269). Spirometry meeting reliability criteria was performed in 87% (n=737) of participants. In the subgroup with a diagnosis of COPD (n=123), only 75.6% (n=93) satisfied Global Initiative in Obstructive Lung Disease (GOLD) criteria for airflow obstruction, and in a healthy subgroup without respiratory symptoms or diagnoses (n=151), 44.4% (n=67) reached GOLD criteria for airflow obstruction and 43.3% (n=29) National Institute of Health and Care Excellence criteria for at least moderate COPD.

Interpretation Spirometry can be successfully performed in the very old, aged 85 years, and may help identify respiratory diseases such as COPD. However interpretation in this age group using current definitions of COPD based on spirometry indices may be difficult and lead to overdiagnosis in a healthy group with transient symptoms.

INTRODUCTION

The very old, aged 85 years and older, are now the most rapidly expanding age sector of most populations worldwide.¹ Data from the 2011 England and Wales Census showed a doubling of the over 85 years age group between 1985 and 2010, from nearly 0.7 million to over 1.4 million,² and numbers are projected to double again between 2010 and 2030.³ This age group frequently uses healthcare resource in primary and secondary care,⁴ and therefore understanding their health

Key messages

What is the key question?

What is the burden of respiratory disease and utility of spirometry in aiding assessment of respiratory health and diagnosis of respiratory disease in community-living 85 year olds in the UK?

What is the bottom line?

The study reveals a substantial burden of respiratory disease and symptoms in 85 year olds but also considerable discordance between physician-diagnosed COPD and confirmatory spirometry evidence in the very old that have important implications for clinical practice.

Why read on?

This study represents the largest and most detailed assessment to date of respiratory health status and challenges of using spirometry criteria in respiratory diagnosis in the very old, aged 85 years and over, which are now the fastest growing sector of the population.

status and burden of disease is important for training of health professionals and for organisation of healthcare provision.

Symptoms relating to the respiratory system, in particular dyspnoea, are common in those 85 years and older with a prevalence of over 40%,⁵ and are frequently a reason for older people to seek health-care. Although it is recognised that many chronic respiratory diseases increase in prevalence and severity with age, it is also clear that dyspnoea is non-specific and may be associated with non-pulmonary morbidities.⁶ In the very old, assessment of respiratory health is further complicated by the physiological changes that occur as part of 'normal' or 'healthy' ageing, such as loss of lung elasticity and reduced thoracic cage movement, which will have an effect on objective measures of lung function.⁷

Current national and international guidelines on the management of COPD have obstructive spirometry (FEV₁/FVC ratio <0.7) as a key diagnostic test directing physicians towards the use of specific



Respiratory epidemiology

respiratory medications.⁸ ⁹ However, the accuracy of lung function criteria for the diagnosis of airflow obstruction or restrictive lung disease in very old people has been questioned due to the intrapulmonary and extrapulmonary physiological changes that occur in this age group as part of normal ageing.¹⁰ This may cause misdiagnosis and inappropriate use of medications in this population. Moreover, a previous study in a population with a mean age of 73 years suggested that COPD may be either overdiagnosed or underdiagnosed depending on the approach taken to defining abnormal lung function.¹¹

This study aimed to address the lack of knowledge about respiratory health, prevalence of lung disease and objective measures of lung function in the very old using baseline data from the Newcastle 85 + Study,⁴ ¹² a large population-based cohort of 85 year olds. Specifically the study aimed to: assess the extent of common respiratory symptoms and the prevalence of physician-diagnosed lung disease, particularly COPD; and to assess the accuracy of COPD diagnosis based on lung function measurements, respiratory symptoms and identification of risk factors, and the degree to which respiratory medication was appropriately prescribed. Finally, in a healthy reference group (HRG), the study aimed to evaluate the applicability of three standard methods of interpreting lung function measurements as normal or abnormal to disentangle the effects of lung disease and 'normal' or 'healthy' ageing on measured lung function.

METHODS

Full details of the Newcastle 85+ Study methodology have been reported.¹² In brief, members of the 1921 birth cohort living in Newcastle upon Tyne or North Tyneside (North-East England) were recruited around their 85th birthday over a 17-month-period spanning 2006 and 2007. Participants included people living at home or in institutional care and regardless of their current health status. More detailed methods are available as online supplementary materials.

Existing diagnoses of respiratory disease, respiratory symptoms, respiratory medications and environmental risk factors

Current and past respiratory diagnoses were identified from a general practice records review (GPRR) using a predetermined checklist of chronic respiratory diseases. Data on use, but not doses, of respiratory medications were also obtained from GPRR. Data on symptoms of breathlessness, cough, wheeze and sputum production were obtained by a structured questionnaire administered as part of a domiciliary multidimensional health assessment (MDHA) conducted by a research nurse in the participant's home or institution. Specifically, participants were asked whether shortness of breath limited their day-to-day activities and responses were then used to assign an Medical Research Council (MRC) dyspnoea score.⁸ Participants were asked about any relevant environmental exposure in their occupation or at home, specifically detailed smoking history and relevant occupational history (including exposure to heavy industry generally as well as the chemical industry, asbestos and coal mining). Two measures of disease burden were used: a disease count (maximum 18 diseases) previously determined in the cohort; and a non-respiratory disease count excluding COPD and other respiratory disease (maximum 16 diseases).⁴ Further details of the individual respiratory diagnoses, medications and chronic non-respiratory diseases included in the disease count are provided (see online supplementary methods).

Lung function measurements

Spirometry and peak flow measurements were performed at the participant's place of residence by a trained research nurse using MicroLab Spirometer and Spida V.5 software (Micro Medical, Rochester, UK). The aim was to obtain three technically satisfactory maximal effort 'blows' to generate reproducible FEV1, FVC and peak expiratory flow measurement (PEF); blows were repeated until this was achieved or maximum effort reached. Blows were assessed for technical adequacy using in-built Spida algorithms. All spirometry curves were assessed independently by a respiratory clinical physiologist and those able to produce at least two adequate blows were included in the analysis. If the necessary quality was lacking they were excluded from analysis. Demispan was measured as a surrogate for height¹³ (calculated using standard equations) and height used with age and gender to calculate predicted values for FEV₁, FVC and peak flow using equations in the UK Department of Health guide.9 Spirometry was classified (see online supplementary table S2) as normal, obstructive or restrictive based on the FEV₁/FVC ratio of 0.7 and the percentage of predicted values for FEV1 and FVC, with obstructive spirometry further classified as mild, moderate or severe based on Global Initiative in Obstructive Lung Disease (GOLD) criteria.¹⁰ In addition, we reanalysed the data using criteria presented by the Global Lung Function Initiative (GLI)¹⁴ which provides alternative prediction model equations validated for ages 3 years to 95 years (see online supplementary tables S3-S5).

Healthy reference group

To establish the distribution of normal lung function in people aged 85 years, we identified a HRG of participants with no respiratory symptoms, no respiratory diagnoses, no current use of respiratory medications and no non-respiratory diagnosis which might influence lung function (eg, Parkinson's disease, kyphoscoliosis, heart failure, ankylosing spondylitis) in their GPRR. Those with a BMI >30 were also excluded from HRG. Lung function in the HRG was compared against equation derived¹⁵ predicted values based on gender and height by three accepted methods: percentage predicted value; lower limit of normal (LLN) using American Thoracic Society/European Respiratory Society (ATS/ERS) criteria;¹⁶ and Z scores.

Statistical methods

Gender differences in respiratory symptoms, diagnoses, environmental exposures and medications were examined using χ^2 and Mann-Whitney U tests. Gender differences in lung function were investigated in the whole sample, COPD group and the HRG using Mann-Whitney U test for continuous measures, χ^2 and Fisher's exact tests for categorised measures and Kruskal-Wallis test for ordered categorised measures. The relationship between FEV₁ and PEF scores was assessed using Pearson's correlation coefficients. Sensitivity analyses were carried out to examine differences between those included and excluded from analysis due to lack of spirometry measures and those with and without an MRC dyspnoea score. All analyses were conducted using Stata V12.0 (StataCorp; College Station, Texas, USA).

RESULTS

Sociodemographic, non-respiratory health characteristics and environmental exposures of the study population Details of the Newcastle 85+ Study population have been reported previously, and the study population was broadly

Respiratory epidemiology




Figure 1 Flow chart illustrating how the total cohort of Newcastle 85+ Study participants was subdivided in the respiratory study sample, demonstrating why different numbers of participants are included in the analyses. The derivation of the study groups are shown in the flow chart; note that for some variables the number of participants included is less than 845 due to missing data, the reasons for which are detailed. The basis for the healthy reference group (HRG) was the 845 participants who had multidimensional health assessment (MDHA) and general practice records review (GPRR) conducted. Of these, 786 (93.0%) had spirometry performed of whom 772 performed it adequately; a further 35 participants with missing demispan were removed (unable to calculate predicted blows), resulting in 737. Participants with at least one respiratory condition, those with respiratory symptoms and those on respiratory medication were excluded which reduced the group size to 170. Other conditions which have an effect on spirometry values were also taken into account leading to exclusion of a further 19 participants. The remaining 151 (17.9% of 845) participants formed the HRG.

sociodemographically representative of the local population, and of England and Wales, including the proportion in institutional care.⁴ Data from MDHA and GPRR was available for 845 participants, 58.2% (845/1453) of those eligible (figure 1); their mean (SD) age was 85.5 (0.4) years, 62.3% (526/845) were female and 99.6% (839/845) were of white ethnic group (table 1). Three-quarters were living in standard housing, 12.8% (108/845) in warden-supported accommodation and 10.2% (86/845) in institutional care. The median (IQR) chronic disease count was 5(3-6) with no significant gender difference

	Men (n=319)	Women (n=526)	Overall cohort (n=845)	p Value
hnicity % (N)				
White	99.4 (316)	99.8 (523)	99.6 (839)	0.272
ving arrangements % (N)				
Standard housing	83.4 (266)	73.2 (385)	77.0 (651)	0.002
Sheltered housing	10.3 (33)	14.3 (75)	12.8 (108)	
Institutional care	6.3 (20)	12.6 (66)	10.2 (86)	
noking % (N)	()			
Never	25.6 (81)	42.0 (220)	35.8 (301)	<0.001
Former	69.9 (221)	51.5 (270)	58.5 (491)	
Current	4.4 (14)	6.5 (34)	5.7 (48)	
ccupational exposures % (N)	(,	0.0 (0.1)		
Heavy industry	41.2 (126)	16.6 (83)	25.9 (209)	<0.001
Coal mining	11.4 (35)	0.0 (0)	4.3 (35)	<0.001
Chemical industry	11.1 (34)	4.0 (20)	6.7 (54)	<0.001
Asbestos exposure	28.9 (88)	1.6 (8)	12.0 (96)	<0.001
espiratory symptoms % (N)	20.3 (00)	1.0 (0)	12.0 (30)	<0.001
Cough	28.3 (88)	25.8 (129)	26.7 (217)	0.425
Wheeze	25.0 (78)	20.2 (101)	22.0 (179)	0.109
Sputum production	40.7 (127)	28.0 (140)	32.9 (267)	<0.001
RC dyspnoea score % (N)	40.7 (127)	20.0 (140)	52.5 (207)	<0.00
1	50.2 (123)	40.5 (143)	44.5 (266)	0.048
2	11.4 (28)	19.0 (67)	15.9 (95)	0.040
3	20.4 (50)	17.6 (62)	18.7 (112)	
4	15.1 (37)	17.0 (60)	16.2 (97)	
5	2.9 (7)	6.0 (21)	4.7 (28)	
espiratory diagnoses % (N)	2.5 (7)	0.0 (21)	4.7 (20)	
COPD	17.9 (57)	15.8 (83)	16.6 (140)	0.429
Asthma	6.9 (22)	12.7 (67)	10.5 (89)	0.007
Bronchiectasis	2.5 (8)	1.5 (8)	1.9 (16)	0.308
Pulmonary fibrosis	0.0 (0)	0.2 (1)	0.1 (1)	1.000
Asbestosis	1.6 (5)	0.0 (0)	0.6 (5)	0.008
Pneumoconiosis	1.3 (4)	0.0 (0)	0.5 (4)	0.020
TB	4.4 (14)	4.9 (26)	4.7 (40)	0.713
espiratory medications	4.4 (14)	4.5 (20)	4.7 (40)	0.71.
Inhaled short-acting β -2 adrenoreceptor agonists	9.1 (29)	11.4 (60)	10.5 (89)	0.288
Inhaled muscarinic antagonists	3.8 (12)	3.8 (20)	3.8 (32)	0.280
Oral theophylline	0.3 (1)	0.5 (3)	0.5 (4)	0.598
Combination short-acting bronchodilators	0.6 (2)	0.0 (0)	0.2 (2)	0.142
Inhaled corticosteroids	5.3 (17)	7.8 (41)	6.9 (58)	0.142
Combination inhaled Corticosteroids and long-acting β -2 adrenoreceptor agonists	1.9 (6)	2.1 (11)	2.0 (17)	0.833
Oral leukotriene receptor antagonists	0.0 (0)	0.4 (2)	0.2 (2)	0.529
Oral neukotnene receptor antagonists Oral mucolytics	0.6 (2)	0.2 (1)	0.2 (2)	0.525
•	0.0 (2)	0.2 (1)	0.4 (5)	0.000
t least one respiratory medication % (N)	12.2 (39)	14.5 (76)	13.6 (115)	0.361
sease count	12.2 (59)	14.5 (70)	15.0 (115)	0.50
	1 (2 6)	F (1 6)	F (2 6)	0.07
median (IQR) omorbid disease count	4 (3–6)	5 (4–6)	5 (3–6)	0.074
median (IQR)	4 (2, 6)	E (1 C)	F (2, 6)	0.04
	4 (3–6)	5 (4–6)	5 (3–6)	0.04

(p=0.074). Although the 845 participants were a non-random sample of the eligible population, data from an additional 188 participants (18%) who opted for GPRR only showed no difference in respiratory diagnoses compared with those who participated fully.

Almost three quarters (74.4%, 235/316) of men and over half of women (58.0%, 304/524) had smoked in their lifetime, although very few (men: 4.4%, 14/316; women: 6.5%, 34/524) were current smokers. A significant proportion of men and women had occupational exposures which may have influenced respiratory health, with much higher prevalence in men (heavy industry: 41.2%, 126/306; coal mining: 11.4%, 35/307; chemical industry: 11.1%, 34/306; asbestos: 28.9%, 88/305), reflecting common historical occupations in this region of the UK (table 1).

Respiratory diagnoses, symptomatology and medication use

The most common physician-diagnosed respiratory condition was COPD with a prevalence of 16.6% (140/845) and no significant gender difference (p=0.43) (table 1). A diagnosis of asthma had been made in 10.5% (89/845) with a predominance in women (men: 6.9%; women: 12.7%; p=0.007). Other respiratory diagnoses were rare.

Chronic cough was self-reported in 26.7% (217/812) and wheeze in 22.0% (179/812) of participants. Regular sputum production was more common in men (men: 40.7%, 127/312; women: 28.0%, 140/500; p<0.001). An MRC dyspnoea score was assigned in 598 (70.8%) participants since in the other participants their activity could be limited by other non-respiratory conditions. Half (123/245) of the men and 40.5% (143/353) of the women allocated an MRC dyspnoea score had no limitations to their daily activities due to breathlessness.

The most frequently prescribed respiratory medications were inhaled short-acting β -2 adrenoreceptor agonists (10.5%, 89/ 845 of participants) followed by inhaled corticosteroids (6.9%, 58/845) (table 1). Only 2.0% (17/845) were taking a

combination inhaler containing corticosteroid and a long-acting β -2 adrenoreceptor agonist. The use of other respiratory medications was unusual (table 1).

Lung function measurements

Spirometry was performed by 786 (93.0%) participants (figure 1), most of whom (98.2%, 772/786) provided at least two adequate blows conforming to ATS/ERS guidelines. Demispan was available for 737 participants with adequate expiratory effort and consistency allowing calculation of predicted spirometry values, with these 737 forming the spirometry group (table 2). Comparison of the spirometry group (n=737) with those excluded due to missing/inadequate spirometry and/ or missing demispan (n=108) showed those excluded were more likely to be female, living in an institution and with previous exposure to the chemical industry, but not significantly different in smoking history; respiratory symptoms, diagnoses or medications; or dyspnoea scores (see online supplementary table S1).

Of the whole spirometry group, 31.2% (230/737) had a normal FEV₁/FVC ratio and 15.2% (112/737) had a restrictive

Table 2	Results of spirometry in the cohort completing spirometry with adequate reproducible blows and demispan available for calculation of	
predicted	blows (n=737)	

	Men (n=293)	Women (n=444)	All (n=737)	p Value*
Actual spirometry median (IC	QR)			
FEV ₁ (l/s)	1.8 (1.4–2.2)	1.2 (1.0–1.5)	1.4 (1.1–1.8)	<0.001†
FVC (l/s)	2.7 (2.2–3.2)	1.8 (1.4–2.1)	2.0 (1.6–2.6)	<0.001†
FEV ₁ /FVC	0.7 (0.6–0.8)	0.7 (0.6–0.8)	0.7 (0.6–0.8)	0.006†
PEF (L/m)	441 (323–604)	283 (196–362)	328 (233–450)	<0.001†
% predicted median (IQR)				
FEV ₁	78.8 (62.4–94.3)	83.4 (68.1–98.8)	81.5 (65.6–97.1)	0.008†
FVC	83.4 (70.3–99.6)	96.6 (79.1–113.7)	90.8 (74.1–108.4)	<0.001†
Spirometry % (N)				
Normal	28.0 (82)	33.3 (148)	31.2 (230)	0.108‡
Restrictive	13.7 (40)	16.2 (72)	15.2 (112)	
Obstructive	58.4 (171)	50.5 (224)	53.6 (395)	
Grading of obstructive spiron	netry§ % (N)			
Mild	35.7 (61)	43.3 (97)	40.0 (158)	0.059¶
Moderate	46.8 (80)	45.1 (101)	45.8 (181)	
Severe	14.6 (25)	9.8 (22)	11.9 (47)	
Very severe	2.9 (5)	1.8 (4)	2.3 (9)	
FEV ₁ % (N)				
Below LLN	25.9 (76)	13.3 (59)	18.3 (135)	<0.001**
Normal range	73.7 (216)	85.6 (380)	80.9 (596)	
Above ULN	0.3 (1)	1.1 (5)	0.8 (6)	
FEV ₁ Z-score				
median (IQR)	1.0 (0.2–1.7)	0.6 (0.0–1.2)	0.8 (0.1–1.4)	<0.001†
FVC % (N)				
Below LLN	21.2 (62)	9.2 (41)	14.0 (103)	<0.001‡
Normal range	77.1 (226)	86.3 (383)	82.6 (609)	
Above ULN	1.7 (5)	4.5 (20)	3.4 (25)	
FVC Z-score				
median (IQR)	0.9 (0.0–1.5)	0.1 (-0.6-0.9)	0.4 (-0.4-1.2)	<0.001†
Oxygen saturation				
median (IQR)	97 (96–98)	97 (96–98)	97 (96–98)	0.513†

*Comparison of men and women.

§This is based on the 395 participant subsample with obstructive spirometry.

LLN, lower limit of normal; PEF, peak expiratory flow; ULN, upper limit of normal.

[†]Mann–Whitney U test. $\pm \gamma^2$ test

 $[\]pm \chi^{-}$ test.

[¶]Kruskal–Wallis test. **Fisher's exact test




Figure 2 Distribution curves of FEV1 and FVC in all participants in spirometry cohort (all, men and women) measured (blue) and predicted (green).




Figure 3 Scatter plots of spirometry and peak expiratory flow in all participants in spirometry cohort.

	Men (n=52)	Women (n=71)	All (n=123)	p Valu
Smoking % (N)				
Never	21.2 (11)	25.7 (18)	23.8 (29)	0.637
Former	67.3 (35)	67.1 (47)	67.2 (82)	
Current	11.5 (6)	7.1 (5)	9.0 (11)	
Occupational exposure % (N)				
Heavy industry	49.0 (25)	19.7 (14)	32.0 (39)	0.001
Coal mining	17.7 (9)	0.0 (0)	7.4 (9)	<0.001
Chemical	13.7 (7)	2.8 (2)	7.4 (9)	0.034
Asbestos	33.3 (17)	7.1 (5)	18.2 (22)	< 0.001
Non-smokers with no occupational exposures % (N)	3.9 (2)	18.3 (13)	12.2 (15)	0.023
Respiratory symptoms % (N)	(-)			
Cough	46.2 (24)	53.5 (38)	50.4 (62)	0.419
Wheeze	53.9 (28)	56.3 (40)	55.3 (68)	0.784
Sputum production	63.5 (33)	54.3 (38)	58.2 (71)	0.310
MRC dyspnoea score % (N)	03.5 (35)	51.5 (50)	50.2 (71)	0.510
1	26.8 (11)	12.5 (7)	18.6 (18)	0.035
2	9.8 (4)	16.1 (9)	13.4 (13)	0.05.
3	34.2 (14)	19.6 (11)	25.8 (25)	
4	22.0 (9)	33.9 (19)	28.9 (28)	
5	7.3 (3)	17.9 (10)	13.4 (13)	
Comorbid respiratory diagnoses % (N)	(0) 0.1	17.5 (10)	15.4 (15)	
Asthma	25.0 (13)	49.3 (35)	39.0 (48)	0.006
Bronchiectasis	7.7 (4)	2.8 (2)	4.9 (6)	0.240
Asbestosis	7.7 (4)	0.0 (0)	3.3 (4)	0.030
				0.050
Pulmonary fibrosis	0.0 (0)	0.0 (0)	0.0 (0)	- 0.17
Pneumoconiosis TB	3.9 (2)	0.0 (0)	1.6 (2)	0.177
	5.8 (3)	9.9 (7)	8.1 (10)	0.516
Viedications % (N)	ЭС Г (10)			0.00-
Inhaled short-acting β -2 adrenoreceptor agonists	36.5 (19)	52.1 (37)	45.5 (56)	0.087
Inhaled muscarinic antagonists	17.3 (9)	22.5 (16)	20.3 (25)	0.477
Oral theophylline	1.9 (1)	4.2 (3)	3.3 (4)	0.637
Combination short-acting bronchodilators	1.9 (1)	0.0 (0)	0.8 (1)	0.423
Inhaled corticosteroids	17.3 (9)	38.0 (27)	29.3 (36)	0.013
Combination inhaled corticosteroids and long-acting β -2 adrenoreceptor agonists	11.5 (6)	12.7 (9)	12.2 (15)	0.849
Oral leukotriene receptor antagonists	0.0 (0)	1.4 (1)	0.8 (1)	1.000
Oral mucolytics	1.9 (1)	1.4 (1)	1.6 (2)	1.000
Oral glucocorticoid therapy	5.8 (3)	4.2 (3)	4.9 (6)	0.697
At least 1 respiratory medication % (N)	46.2 (24)	66.2 (47)	57.7 (71)	0.026
Disease count				
median (IQR)	5 (4–7)	6 (5–7)	6 (4–7)	0.156
Non-respiratory disease count				
median (IQR)	5 (4–6)	6 (5–7)	6 (4–7)	0.064

‡Fisher's exact test.

§Mann–Whitney U test. Denominators vary due to missing values.

pattern. Obstructive spirometry was the most common finding (men: 58.4%, 171/293; women: 50.5%, 224/444) but with no gender difference in the spread of severity (table 2). Measured values of FEV₁, FVC and PEF in the spirometry group were normally distributed but with a much wider distribution range than that of the predicted values (figure 2). Scatter plots of the measured FEV₁ and FVC against the predicted values showed more participants with measured values below the predicted values than above suggesting a downward shift in the population as a whole (figure 3). The spread of FEV₁ measurements around the predicted values was much wider in men than women.

Prevalence and accuracy of physician-diagnosed COPD

Of the spirometry group, 16.7% (123/737) had physiciandiagnosed COPD (COPD group) of whom 57.7% (71/123) were female and 23.8% (29/123) reported being 'never smokers' (table 3). More than half of the 'never smokers' with a COPD diagnosis had no occupational exposures either.

In the COPD group, only 45.5% (56/123) were taking shortacting inhaled β -2 adrenoreceptor agonist bronchodilator therapy, 20.3% (25/123) were taking inhaled long-acting muscarinic antagonists, 41.5% (51/123) were on inhaled corticosteroids either as monotherapy (36/51) or in combination with a

	Men (n=52)	Women (n=71)	All (n=123)	p Value*
Actual median (IQR)				
FEV ₁	1.4 (1.1–1.8)	1.0 (0.7–1.1)	1.1 (0.8–1.4)	<0.001†
FVC	2.4 (2.0–3.1)	1.6 (1.3–1.9)	1.9 (1.5–2.3)	<0.001†
FEV ₁ /FVC	0.6 (0.5–0.7)	0.6 (0.5–0.7)	0.6 (0.5–0.7)	0.591†
PEF	382.5 (243–519)	218 (144–290)	259 (191–380)	<0.001†
%predicted median (IQR)				
FEV ₁	63.5 (50.9–73.4)	64.2 (51.7–79.9)	64.2 (51.3–76.4)	0.609†
FVC	77.4 (64.2–94.1)	87.6 (70.4–101.0)	82.8 (68.2–99.8)	0.040†
Spirometry %(N)				
Normal	7.7 (4)	8.5 (6)	8.1 (10)	0.959‡
Restrictive	15.4 (8)	16.9 (12)	16.3 (20)	
Obstructive	76.9 (40)	74.7 (53)	75.6 (93)	
Obstructive spirometry§ %(N)				
Mild	10.0 (4)	20.8 (11)	16.1 (15)	0.190¶
Moderate	60.0 (24)	56.6 (30)	58.1 (54)	
Severe	27.5 (11)	20.8 (11)	23.7 (22)	
Very severe	2.5 (1)	1.9 (1)	2.2 (2)	
FEV ₁ %(N)				
Below LLN	48.1 (25)	33.8 (24)	39.8 (49)	0.137**
Normal range	51.9 (27)	66.2 (47)	60.2 (74)	
Above ULN	0.0 (0)	0.0 (0)	0.0 (0)	
FEV ₁ Z-score				
median (IQR)	1.6 (1.2–2.2)	1.3 (0.7–2.0)	1.5 (0.9–2.0)	0.039†
FVC %(N)				
Below LLN	30.8 (16)	14.1 (10)	21.1 (26)	0.043**
Normal range	69.2 (36)	84.5 (60)	78.1 (96)	
Above ULN	0.0 (0)	1.4 (1)	0.8 (1)	
FVC Z-score				
median (IQR)	1.1 (0.3–1.8)	0.6 (0.0–1.2)	0.8 (0.0–1.6)	0.008†
Oxygen saturation				
median (IQR)	97 (96–98)	97 (95–98)	97 (95–98)	0.521†

*Comparison of men and women †Mann–Whitney U test.

 $\pm \gamma^2$ test.

§This is based on the 93 participant subsample with obstructive spirometry.

LLN, lower limit of normal; PEF, peak expiratory flow; ULN, upper limit of normal.

long-acting β -agonist (15/51). There was minimal use of theophylline preparations, oral mucolytics or oral leukotriene receptor antagonists and none of the COPD group used home oxygen (table 3). The proportion of the COPD group that were on at least one respiratory medication differed significantly between men and women (men: 46.2%, 24/52; women: 66.2%, 47/71; p=0.026), although a sizeable proportion (42.3%, 52/123) of those with a COPD diagnosis were not on any (table 3). There was a significant overlap in the diagnoses of asthma and COPD with 61% (48/78) of those with an asthma diagnosis also being diagnosed with COPD.

Respiratory symptoms were common but not universal in the COPD group with 50.4% (62/123) reporting cough and 58.2% (71/123) sputum production. Nevertheless 26.8% (11/52) of men and 12.5% (7/71) of women with a COPD diagnosis had only minimal breathlessness (MRC dyspnoea score=1).

Only 75.6% (93/123) of the COPD group had obstructive spirometry by GOLD criteria (table 4). There was no gender difference in severity of airflow obstruction (based on % predicted FEV₁) and only 63.4% (78/123) of the COPD group fulfilled the UK National Institute of Health and Care Excellence (NICE) guidelines spirometry definition of moderate, severe or

very severe disease (table 4). Furthermore, only 63.4% (78/123) of the COPD group fulfilled the UK NICE guidelines spirometry definition of moderate, severe or very severe disease. When FEV₁ was classified by the LLN approach, 48.1% (25/52) of men and 33.8% (24/71) of women from the COPD group fell below the LLN with all other participants falling between the LLN and upper limit of normal, suggesting that a substantial proportion (60.2%, 74/123) of those with physician-diagnosed COPD had an FEV₁ in the normal range and/or no airflow obstruction on spirometry measurement. When applying the GLI prediction models to the COPD group, 48.1% (25/52) men and 50.7% (36/71) women satisfied criteria for airflow obstruction (see online supplementary table S4). The degree of agreement between physician-diagnosed COPD and spirometric evidence of airflow obstruction using either GOLD or GLI criteria is poor when assessed by the McNemar test (see online supplementary table S6).

Assessment of lung function in an HRG

Figure 1 shows the derivation of the HRG which comprised 20.5% (151/737) of the spirometry cohort (table 5). The distribution of measured and predicted FEV₁, FVC and PEF in this

[¶]Kruskal–Wallis test.

^{**}Fisher's exact test.

	Men (n=57)	Women (n=94)	All (n=151)	p Value*
Actual median (IQR)				
FEV ₁	2.0 (1.7–2.4)	1.4 (1.2–1.6)	1.5 (1.2–2.0)	<0.001†
FVC	2.9 (2.4–3.5)	1.9 (1.6–2.2)	2.1 (1.8–2.8)	<0.001†
FEV ₁ /FVC	0.7 (0.6–0.8)	0.7 (0.7–0.8)	0.7 (0.6–0.8)	0.244†
PEF	515 (340–647)	329.5 (243–417)	367 (263–515)	<0.001†
%predicted median (IQR)				
FEV ₁	90.1 (67.6–103.8)	93.8 (78.6–106.0)	91.6 (76.0–106.0)	0.154†
FVC	92.3 (72.0–107.7)	101.2 (85.2–121.7)	97.5 (80.6–115.2)	0.006†
Spirometry %(N)				
Normal	38.6 (22)	44.7 (42)	42.4 (64)	0.764‡
Restrictive	14.0 (98)	12.8 (12)	13.3 (20)	
Obstructive	47.4 (27)	42.6 (40)	44.4 (67)	
Obstructive spirometry§ %(N)				
Mild	48.2 (13)	62.5 (25)	56.7 (38)	0.137¶
Moderate	33.3 (9)	32.5 (13)	32.8 (22)	
Severe	11.1 (3)	5.0 (2)	7.5 (5)	
Very severe	7.4 (2)	0.0 (0)	3.0 (2)	
FEV ₁ %(N)				
Below LLN	21.1 (12)	5.3 (5)	11.3 (17)	0.008**
Normal range	77.2 (44)	93.6 (88)	87.4 (132)	
Above ULN	1.8 (1)	1.1 (1)	1.3 (2)	
FEV ₁ Z-score				
median (IQR)	0.5 (-0.2-1.6)	0.3 (-0.2-0.9)	0.3 (-0.2-1.0)	0.071†
FVC %(N)				
Below LLN	19.3 (11)	1.1 (1)	8.0 (12)	<0.001**
Normal range	79.0 (45)	91.5 (86)	86.8 (131)	
Above ULN	1.8 (1)	7.5 (7)	5.3 (8)	
FVC Z-score				
median (IQR)	0.4 (-0.4-1.5)	-0.1 (-0.9-0.6)	0.1 (-0.7-0.9)	0.004†
Oxygen saturation				
median (IQR)	98 (96–98)	98 (97–98)	98 (96–98)	0.970†

*Comparison of men and women †Mann–Whitney U test.

 $\pm \gamma^2$ test.

§This is based on the 67 participant subsample with obstructive spirometry.

**Fisher's exact test.

LLN, lower limit of normal; PEF, peak expiratory flow; ULN, upper limit of normal.

group, by gender, are shown in figure 4 and table 5, with scatter plots of measured versus predicted FEV_1 and FVC by gender in figure 5.

Approximately half of the HRG (men: 47.4%, 27/57; women: 42.6%, 40/94) had a spirometry definition of airflow obstruction by GOLD criteria (table 5) yet did not fulfil the requirements for a diagnosis of COPD through lack of symptoms. Interestingly 19.2% (29/151) fulfilled a spirometry definition of at least moderate COPD using NICE criteria (obstructive spirometry and an FEV₁ <80% predicted). The measured best PEF median (IQR) for this group was 367 (263–515) L/min, significantly higher in men (515 (340–647) L/min) than in women (329.5 (243–417) L/min) (p<0.001), and highly correlated with FEV₁ (figure 5). When applying the GLI criteria to HRG only 17.5% (10/57) men and 16% (15/94) women (see online supplementary table 5) fulfilled criteria for airflow obstruction suggesting that GLI offered superiority to GOLD in spirometry interpretation in this age group.

The measured spirometry values in HRG were compared with equation-derived¹⁵ predicted values based on gender and height using three different accepted approaches: percentage predicted value, LLN and Z scores (table 5). The median (IQR)

percentage predicted value FEV₁ in HRG was 90.1% (67.6–103.8%) in men and 93.8% (78.6–106.0%) in women. The measured FEV₁ fell below LLN in 11.3% (17/151) of participants with a large gender difference (men: 21.1%, 12/57; women: 5.3%, 5/94; p=0.008). A significant gender difference was also found for the proportion of measured FVC falling below LLN with observed gender difference in the median Z-scores (table 5).

DISCUSSION

This study presents the first evaluation of respiratory symptomatology, respiratory disease prevalence and objectively measured lung function in a large UK population-based single-year birth cohort of 85 year olds. It provides insight into the burden of respiratory disease and degree of respiratory impairment in very old people in an urban setting, and illustrates a population with substantial environmental exposures and smoking history, even in women. Furthermore, despite the higher rate of cognitive impairment with age, 93% of our cohort performed spirometry and of these 98% did so successfully which challenges reluctance to use spirometry in the very old and

[¶]Kruskal–Wallis test.




Figure 4 Distribution curves of FEV₁ and FVC of participants in the healthy reference group (all, men and women) measured (blue) and predicted (green).

dispels misconceptions that they cannot perform spirometry successfully.


The participants are long-lived, and survivors of some of the most remarkable historical periods of our time, starting in the year of their birth immediately post World War I and the 1918 Spanish influenza pandemic. There were high levels of deprivation, and unemployment across Britain reached 17% in 1921. This period was pre welfare state, Housing Act (1930), Clean Air Act and widespread use of penicillin (1940). Many of the participants would have been nearing retirement age when the 1986 WHO: Ottawa Charter for Health Promotion was introduced—smoking rates are particularly high for men.

It is therefore not unexpected that a high prevalence of physician-diagnosed COPD (16.7%) was identified compared with previous self-reports of COPD of 10% in 65–74 year olds in the 2010 Health Survey for England.¹⁷ Nevertheless there were signs of potential misdiagnosis of COPD with a significant proportion of those with physician-diagnosed COPD having no evidence of airflow obstruction on spirometry, no smoking or occupational history and minimal symptoms. At the same time, a high proportion of our HRG fulfilled spirometry criteria for COPD using current GOLD/NICE guidelines, though use of LLN and GLI criteria rather than GOLD or NICE guidelines might reduce levels of misdiagnosis.

The risk of respiratory impairment increases with age due to the cumulative lifetime effect of environmental insults from active and passive cigarette smoking, air pollution, occupational dusts and infections.¹⁸ ¹⁹ When this risk is added to the changes which occur in the respiratory system as part of normal ageing, including reduced ventilatory control, reduced respiratory muscle strength, increased compliance and less favourable respiratory mechanics due to reduced movement of the chest wall,⁷ it is not surprising that symptoms of cough, wheeze and dyspnoea are common in older people. All of these factors are likely to reduce measured lung function, which has been shown to be an independent risk factor for frailty and death.^{20–22} Distinguishing physiological age-related loss of lung function from a pathological disease process in the lungs is further complicated by a reduced perception of respiratory symptoms that occurs with increasing age as demonstrated by significantly reduced awareness of measured bronchospasm after a methacholine challenge in older compared with younger patients.²³ Despite the high prevalence of chronic lung disease and respiratory symptoms, we found a significant proportion, 50% of men and 40% of women, with no reported limitations due to breathlessness suggesting many are either able to function very well or have a poor perception of symptoms.

The strengths of this work are the comprehensive assessment of respiratory health and lung disease in a large populationbased cohort of 85 year olds, including those in institutional care and those with cognitive impairment, in a stable urban setting and with little ethnic diversity. The cohort of >800 participants was achieved through engagement with 83% of the general practices in the area and a consent rate of almost 60% in those approached to participate. Previous studies of respiratory health in older subjects have relied on self-reported diagnoses whereas in our study the use of general practice records significantly improves the validity of our findings.^{24 25} Furthermore by conducting spirometry in the participant's place of residence using trained research nurses we were able to achieve a very high uptake of this assessment, in contrast to the known selection bias if participants had been required to attend a clinic for assessment. Although participants opting in for the health assessment were not a random sample of those eligible, there was little evidence to suggest they had more or less respiratory disease than those refusing the health assessment. In








Figure 5 Scatter plots of spirometry and peak expiratory flow in the healthy reference group.

addition they were sociodemographically representative of their England and Wales birth cohort.⁴ A potential limitation of the study is that those who agreed to participate may be healthier and less frail than those who declined to participate and those with cognitive impairment may have been under-represented. Although some information was collected about why those invited declined to participate, we obviously do not have objective data on their respiratory health or disease burden. However the prevalence of COPD of 16.7% in those who agreed to MDHA and GPRR (n=845) was very similar to the prevalence of 16.5% reported previously in all participants with GPRR data (n=1030),⁴ suggesting that in terms of COPD, those agreeing to MDHA had similar respiratory health profiles to the larger study population. While 85 year olds in this urban area in North-East England are sociodemographically and ethnically similar to the same birth cohort in England and Wales as a whole, they may differ from those in other parts of the world.

This study has revealed a substantial burden of respiratory symptoms and respiratory disease, particularly COPD, in a cohort of the very old aged 85 years; a group with substantial environmental exposures recorded through smoking and occupational exposure, which are known risk factors for lung disease. Despite these observations, we show a good proportion of participants functioning well with no respiratory symptoms or diagnoses. Lung function tests revealed only 75.6% of the COPD group satisfied spirometry criteria whereas 44% of the healthy group satisfied spirometry criteria for COPD using GOLD criteria. Healthcare professionals need to recognise that spirometry can be reliably assessed in the vast majority of this age group but care is needed as to how this is interpreted. Current definitions of COPD based on spirometry may lead to overdiagnosis in a group with transient symptoms and 'normal' lung ageing, whereas at the same time failure to use spirometry to assess symptoms in this age group may lead to mislabelling those with breathlessness or cough as having COPD when there are other explanations.

Acknowledgements The authors thank the 85 year olds of Newcastle and North Tyneside, and their families and carers, for the generous donation of their time and personal information. The authors also thank the research nurses, data manager, project secretary, and the North of England Commissioning Support Unit and local general practitioners and their staff.

Contributors AJF: study design; data preparation; literature review; data analysis and interpretation; development and writing of the paper. MEY: literature review, statistical analysis and interpretation of data; development and critical review of paper drafts. JC: study design; supervision of data collection; data preparation; literature review; data analysis and interpretation; and the development and writing of the paper. TS: study design; supervision of data collection; literature review; development of paper and critical review of paper drafts. TBLK: overall leadership of the Newcastle 85+ Study; study design; and critical review of paper drafts. KD: study design; participant recruitment; supervision of data collection; data preparation; and critical review of paper drafts. CJ: study design; supervision of statistical analysis; data interpretation; and critical review of paper drafts. PAC: study design; data interpretation; and critical review of paper drafts.

Funding UK Medical Research Council and Biotechnology and Biological Sciences Research Council (G0500997), Dunhill Medical Trust (R124/0509); Newcastle Healthcare Charity; NIHR Newcastle Biomedical Research Centre.

Competing interests The authors declare: the authors' institution had financial support from the UK Medical Research Council and the Biotechnology and Biological Sciences Research Council (G0500997), the Dunhill Medical Trust (a privately endowed foundation having no connection with tobacco industries) and the Newcastle Healthcare Charity in terms of funding the submitted work; CJ was supported by the AXA Research Fund from 2010 to 2015.

Patient consent Obtained.

Ethics approval The research complied with the requirements of the Declaration of Helsinki. Ethical approval was obtained from the Newcastle and North Tyneside 1 Research Ethics Committee (reference number 06/Q0905/2).

Provenance and peer review Not commissioned; externally peer reviewed.

Open Access This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/

REFERENCES

- 1 United Nations. World Population Ageing: 1950–2050, 2002. http://www.un.org/ esa/population/publications/worldageing19502050/ (accessed Jan 2014).
- 2 Office for National Statistics. 2011 Census—Population and Household Estimates for England and Wales, March 2011, 2012.

Respiratory epidemiology

- 3 House of Lords Select Committee on Public Service and Demographic Change. *Ready for Ageing?* The Stationery Office Limited, 2013.
- 4 Collerton J, Davies K, Jagger C, et al. Health and disease in 85 year olds: baseline findings from the Newcastle 85+ cohort study. BMJ 2009;339:b4904.
- 5 Tessier JF, Nejjari C, Letenneur L, et al. Dyspnea and 8-year mortality among elderly men and women: the PAQUID cohort study. Eur J Epidemiol 2001;17:223–9.
- 6 van Mourik Y, Rutten FH, Moons KG, et al. Prevalence and underlying causes of dyspnoea in older people: a systematic review. Age Ageing 2014;43:319–26.
- 7 Vaz Fragoso CA, Lee PJ. The aging lung. J Gerontol A Biol Sci Med Sci 2012;67:233–5.
- 8 Fletcher CM, Elmes PC, Fairbairn AS, et al. The significance of respiratory symptoms and the diagnosis of chronic bronchitis in a working population. Br Med J 1959;2:257–66.
- 9 Department of Health. A guide to performing quality assured diagnostic spirometry. Department of Health, 2013.
- 10 GOLD. Spirometry for health care providers. Global Initiative for Chronic Obstructive Lung Disease, 2010.
- 11 Guder G, Brenner S, Angermann CE, et al. GOLD or lower limit of normal definition? A comparison with expert-based diagnosis of chronic obstructive pulmonary disease in a prospective cohort-study. *Respir Res* 2012;13:13.
- 12 Collerton J, Barrass K, Bond J, et al. The Newcastle 85+ study: biological, clinical and psychosocial factors associated with healthy ageing: study protocol. BMC Geriatr 2007;7:14.
- 13 Hirani V, Mindell J. A comparison of measured height and demi-span equivalent height in the assessment of body mass index among people aged 65 years and over in England. *Age Ageing* 2008;37:311–17.
- 14 Quanjer PH, Stanojevic S, Cole TJ, et al. Multi-ethnic reference values for spirometry for the 3–95-yr age range: the global lung function 2012 equations. Eur Respir J 2012;40:1324–43.
- 15 Quanjer PH, Tammeling GJ, Cotes JE, *et al.* Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European

Community for Steel and Coal. Official Statement of the European Respiratory Society. *Eur Respir J Suppl* 1993;16:5–40.

- 16 Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. Eur Respir J 2005;26:319–38.
- 17 National Health Service. *Health Survey for England 2010, Respiratory Health*. The NHS Information Centre, 2011.
- 18 Boezen HM, Rijcken B, Schouten JP, et al. Breathlessness in elderly individuals is related to low lung function and reversibility of airway obstruction. Eur Respir J 1998;12:805–10.
- 19 Vaz Fragoso CA, Gill TM. Respiratory impairment and the aging lung: a novel paradigm for assessing pulmonary function. J Gerontol A Biol Sci Med Sci 2012;67:264–75.
- 20 Buchman AS, Boyle PA, Leurgans SE, et al. Pulmonary function, muscle strength, and incident mobility disability in elders. Proc Am Thorac Soc 2009;6:581–7.
- 21 Lyyra TM, Leskinen E, Heikkinen E. A cohort study found good respiratory, sensory and motor functions decreased mortality risk in older people. J Clin Epidemiol 2005;58:509–16.
- 22 Smith M, Zhou M, Wang L, et al. Peak flow as a predictor of cause-specific mortality in china: Results from a 15-year prospective study of 170 000 men. Int J Epidemiol 2013;42:803–15.
- 23 Connolly MJ, Crowley JJ, Charan NB, et al. Reduced subjective awareness of bronchoconstriction provoked by methacholine in elderly asthmatic and normal subjects as measured on a simple awareness scale. Thorax 1992;47:410–13.
- 24 Simpson CF, Boyd CM, Carlson MC, et al. Agreement between self-report of disease diagnoses and medical record validation in disabled older women: factors that modify agreement. J Am Geriatr Soc 2004;52:123–7.
- 25 Kriegsman DM, Penninx BW, van Eijk JT, *et al.* Self-reports and general practitioner information on the presence of chronic diseases in community dwelling elderly. A study on the accuracy of patients' self-reports and on determinants of inaccuracy. *J Clin Epidemiol* 1996;49:1407–17.